New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
08:41 EDTAVNR, IPXLAvanir sues Impax over planned Nuedexta generic, Bloomberg reports
Avanir Pharmaceuticals (AVNR) is suing Impax Laboratories (IPXL) for allegedly infringing a new patent for the drug Nuedexta and planning to market a generic version of the drug before the patent expires in 2023, reported Bloomberg, citing a complaint filed in a federal court in Delaware. Reference Link
News For AVNR;IPXL From The Last 14 Days
Check below for free stories on AVNR;IPXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 6, 2014
07:41 EDTIPXLImpax sees FY14 adjusted gross margin as percent of revenue to be upper 50%
Sees FY14 R&d expenses $82M-$88M; Sees FY14 generic R&D expenses $46M-$49M; Sees FY14 brand R&D expenses $36M-$39M; Sees FY14 patent litigation expenses $11M-$13M; Sees FY14 SG&A expenses $115M-$120M; Sees FY14 CapEx $40M-$45M; Sees FY14 Hayward facility remediation costs of $25M-$30M; Sees FY14 effective tax rate of 32%-34%.
07:39 EDTIPXLImpax 'remains excited about business development and M&A landscape'
07:39 EDTIPXLImpax reports Q2 adjusted EPS 60c, consensus 36c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use